Relationship between glucagon-like peptide-1 receptor agonist use and incidence of trigger finger in patients with type 2 diabetes

Key Points

• Trigger finger incidence is associated with the use of glucagon-like peptide-1 receptor agonists.
• A 30% increase in trigger finger cases was observed in patients using GLP-1 agonists compared to those who did not.
• Assessment of the correlation between glucagon-like peptide-1 receptor agonist use and trigger finger incidence involved data from diabetes management records.
• These findings imply a need for monitoring trigger finger symptoms in patients receiving GLP-1 receptor agonist treatment.